Study population baseline characteristics by exposure category: persons aged 65–84 years with a first myocardial infarction as principal diagnosis during 1995–2006
| Preventive drug dispensed within 28 days postdischarge | ||||
|---|---|---|---|---|
| Panel A | None | BB only | Statins only | ACEi/ARB only |
| % (n=2316) | % (n=658) | % (n=496) | % (n=983) | |
| Age (years) | ||||
| 65–69 | 26.8 (620) | 23.7 (156) | 27.4 (136) | 16.3 (160) |
| 70–74 | 25.4 (588) | 24.6 (162) | 29.8 (148) | 24.0 (236) |
| 75–79 | 23.7 (548) | 29.0 (191) | 22.0 (109) | 27.1 (266) |
| 80–84 | 24.2 (560) | 22.6 (149) | 20.8 (103) | 32.7 (321) |
| Gender | ||||
| Male | 60.6 (1403) | 64.6 (425) | 63.5 (315) | 58.3 (573) |
| Female | 39.4 (913) | 35.4 (233) | 36.5 (181) | 41.7 (410) |
| Previous other IHD (% within 5 years) | 25.4 (587) | 22.5 (148) | 29.8 (148) | 34.1 (335) |
| Previous CARP (% within 5 years) | 16.8 (390) | 12.6 (83) | 31.4 (156) | 13.7 (135) |
| Previous HF (% within 5 years) | 11.4 (263) | 5.6 (37) | 9.7 (48) | 19.7 (194) |
| Drugs dispensed within 2 months prior to admission | ||||
| BB (%) | 9.7 (224) | 22.6 (149) | 17.5 (87) | 17.8 (175) |
| ST (%) | 8.8 (203) | 12.3 (81) | 40.7 (202) | 13.1 (129) |
| ACEi/ARB (%) | 16.3 (378) | 20.2 (133) | 30.6 (152) | 45.2 (444) |
| Drugs dispensed within 28 days postdischarge | ||||
| Aspirin and/or clopidogrel (%) | 11.1 (258) | 44.8 (295) | 49.2 (244) | 43.1 (424) |
| n (SD) | n (SD) | n (SD) | n (SD) | |
| Mean survival days (1 year) | 328.0 (90.0) | 332.8 (85.3) | 314.5 (101.1) | 317.4 (101.2) |
| Deaths (1 year) | 314 | 73 | 48 | 178 |
| Crude mortality rate (1 year)* | 95.7 | 21.9 | 15.3 | 56.1 |
| Mean survival days (until 2006) | 1770.1 (1197.2) | 1935.3 (1250.3) | 1258.1 (1031.1) | 1292.3 (1031.8) |
| Deaths (until 2006) | 1016 | 289 | 137 | 582 |
| Crude mortality rate (until 2006)* | 57.4 | 14.9 | 10.9 | 45.0 |
| Panel B | BB+ST | BB+ACEi/ARB | ST+ACEi/ARB | BB+ST+ACEi/ARB |
| % (n=729) | % (n=903) | % (n=1046) | % (n=2449) | |
| Age (years) | ||||
| 65–69 | 30.7 (224) | 22.7 (205) | 25.0 (262) | 29.8 (731) |
| 70–74 | 27.2 (198) | 24.0 (217) | 28.2 (295) | 28.0 (687) |
| 75–79 | 26.3 (192) | 28.0 (253) | 27.4 (287) | 25.6 (628) |
| 80–84 | 15.8 (115) | 25.2 (228) | 19.3 (202) | 16.5 (403) |
| Gender | ||||
| Male | 60.0 (437) | 63.9 (577) | 61.3 (641) | 62.1 (1521) |
| Female | 40.0 (292) | 36.1 (326) | 38.7 (405) | 37.9 (928) |
| Previous other IHD (% within 5 years) | 21.5 (157) | 23.7 (214) | 30.6 (320) | 17.6 (432) |
| Previous CARP (% within 5 years) | 23.3 (170) | 7.2 (158) | 31.2 (326) | 31.8 (779) |
| Previous HF (% within 5 years) | 4.9 (36) | 9.4 (85) | 11.8 (123) | 4.9 (119) |
| Drugs dispensed within 2 months prior to admission | ||||
| BB (%) | 20.0 (146) | 23.8 (215) | 20.5 (214) | 23.2 (567) |
| ST (%) | 30.0 (219) | 12.7 (115) | 40.8 (427) | 32.0 (785) |
| ACEi/ARB (%) | 23.9 (174) | 39.6 (358) | 47.1 (493) | 39.5 (968) |
| Drugs dispensed within 28 days postdischarge | ||||
| Aspirin and/or clopidogrel (%) | 59.7 (435) | 55.6 (502) | 59.6 (623) | 72.0 (1762) |
| n (SD) | n (SD) | n (SD) | n (SD) | |
| Mean survival days (1 year) | 336.9 (76.4) | 332.4 (85.8) | 322.8 (95.0) | 323.1 (95.0) |
| Deaths (1 year) | 38 | 89 | 103 | 132 |
| Crude mortality rate (1 year)* | 11.3 | 26.8 | 31.9 | 40.8 |
| Mean survival days (until 2006) | 1720.9 (1116.6) | 1673.6 (1147.4) | 1144.4 (871.1) | 1115.3 (867.0) |
| Deaths (until 2006) | 154 | 369 | 295 | 405 |
| Crude mortality rate (until 2006)* | 8.9 | 22.0 | 25.8 | 36.3 |
*Per 100 person days.
ACEi/ARB; ACE inhibitors or angiotensin II-receptor blockers; BB+, β blocker; CARP, coronary artery revascularisation procedure; HF, heart failure; IHD, ischaemic heart disease; ST, statin.